If you are wondering who discovered DSIP, the answer is a Swiss research team led by Guido A. Schoenenberger and Marcel Monnier. In March 1977, the pair published the chemical sequence of delta sleep-inducing peptide in PNAS. They worked at Basel Medical School's Department of Surgery at Kantonsspital and the University of Basel's Institute of Physiology.
That 1977 paper capped more than a decade of experiments on rabbit blood. Monnier and Schoenenberger wanted to know whether a chemical signal in the bloodstream could trigger slow-wave sleep. For a plain overview of the molecule itself, see our guide to what DSIP is.
Isolating a nine-amino-acid sequence in rabbits was a major laboratory milestone, not proof of a human sleep treatment. A 2006 review questioned its natural origin, and a 2011 study proposed a precursor candidate without establishing DSIP biosynthesis.
Who discovered DSIP and what were they testing?
The question behind DSIP started long before the Basel researchers teamed up. Scientists wanted to know if sleep builds up a chemical signal in body fluids that can pass to another animal.
As a 2025 historical review of sleep-factor research recounts, the earliest transfer experiments used dogs. Ishimori in Japan in 1909, followed by Legendre and Piéron in France in 1910 and 1913, transferred fluid from sleep-deprived dogs into rested dogs. Those early experiments inspired later sleep-factor research, though the material in those dog studies was not DSIP.
Marcel Monnier picked up the blood-transfer question in Basel in the early 1960s. According to a 1984 review by Markus V. Graf and Abba J. Kastin, Monnier began with rabbit cross-circulation experiments in 1963. Cross-circulation connected the bloodstreams of two rabbits so blood from a sleeping animal flowed into an awake one.
Next, the Basel lab turned to dialysis, which filters small molecules out of blood across a membrane. In a November 1964 report in Science, Monnier and L. Hoesli filtered brain blood from rabbits during electrically induced sleep or wakefulness. Fluid filtered from sleeping donors produced sleep-like brain waves in recipient rabbits, while fluid from alert donors caused arousal.
Schoenenberger and Monnier then combined their Basel teams and reported partial purification of the substance in 1972. In a November 1975 paper in Pflugers Archiv, Monnier, L. Dudler, R. Gächter, and Schoenenberger called the candidate "sleep factor delta." That 1975 study compared the candidate peptide across rabbit brain blood, systemic blood, and spinal fluid.
The 1977 isolation and how DSIP got its name
In March 1977, Schoenenberger and Monnier published their final chemical characterization in PNAS. They identified a chain of nine amino acids, the building blocks of proteins: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.
To test whether that exact sequence matched the natural extract, the researchers built a synthetic copy in the laboratory. They infused the synthetic peptide or comparison compounds into the brain ventricles of 58 rabbits, including control animals. The experiment ran under double-blind conditions, meaning the researchers scoring the results did not know which rabbit received which fluid.
The name "delta sleep-inducing peptide" came directly from that rabbit assay. Researchers tracked each animal's electroencephalogram (EEG), a recording of electrical brain waves. Only rabbits given synthetic DSIP showed a significant, specific increase in slow-wave delta and spindle activity on their EEG.
That naming detail matters if you are reading about DSIP today. The word "inducing" described an electrical brain-wave shift in rabbits during a short lab test, not a proven cure for human insomnia.
| Year | Researchers | Milestone |
|---|---|---|
| 1909–1913 | Ishimori; Legendre and Piéron | Early dog fluid-transfer studies spark the search for sleep factors |
| 1963–1964 | Monnier and Hoesli | Rabbit cross-circulation and blood-dialysis studies in Basel |
| 1972–1975 | Monnier, Schoenenberger, and colleagues | Partial purification and "sleep factor delta" blood fraction studies |
| 1977 | Schoenenberger and Monnier | Nine-amino-acid sequence characterized and named DSIP in PNAS |
| 1981 | Schneider-Helmert and colleagues | First intravenous synthetic DSIP study in six healthy volunteers |
| 1992 | Bes and colleagues | Controlled study in 16 chronic insomnia patients finds only weak effects |
| 2006 | Kovalzon and Strekalova | Review notes no DSIP gene, precursor protein, or receptor has been isolated |
| 2011 | Mikhaleva and colleagues | Moscow team proposes a related sequence in JMJD1B proteins as a candidate lead |
| 2026 | FDA staff presentation to PCAC | FDA proposes against placing emideltide forms on the 503A Bulks List |
Parallel sleep-factor hunts and early human studies
DSIP was not the only candidate sleep substance under investigation during the 1960s and 1970s. At Harvard Medical School, John Pappenheimer led a separate research program starting with goat spinal fluid in 1967. Pappenheimer called his unknown sleep-promoting substance "Factor S."
In an October 1982 paper in PNAS, J. M. Krueger, Pappenheimer, and M. L. Karnovsky tested muramyl peptides purified from human urine. Synthetic muramyl peptides increased slow-wave sleep in animals and were fever-producing; they may also disturb the body's automatic functions. Factor S and muramyl peptides were completely distinct molecules from the Basel group's DSIP.
Meanwhile, the Swiss team moved synthetic DSIP into early human testing. In an August 1981 clinical paper, D. Schneider-Helmert, F. Gnirss, Monnier, J. Schenker, and Schoenenberger reported an early double-blind crossover study. Six healthy volunteers, four men and two women, received synthetic DSIP by intravenous (into-a-vein) infusion.
Later human trials for chronic insomnia produced mixed and underwhelming results. In a 1992 double-blind study of 16 insomnia patients, F. Bes and colleagues found weak effects and no change in subjective sleep quality. You can read the full clinical outcomes in DSIP benefits and see how study infusions were structured in DSIP dosage.
Where does DSIP come from in the body?
When scientists discover a natural signaling peptide, they usually map its biological assembly line next. That means finding the gene that codes for it, the larger precursor protein it is cut from, and the cell receptor it unlocks. A 2006 review described those parts of the DSIP map as unresolved.
Questions appeared early. In their 1984 review, Graf and Kastin openly asked whether DSIP was truly a sleep factor and whether it occurred naturally. Labs even built artificial genes to make DSIP in bacteria, yet no natural mammalian gene turned up.
In an April 2006 review in the Journal of Neurochemistry, Vladimir M. Kovalzon and Tatyana V. Strekalova called DSIP "a still unresolved riddle." They pointed out that no DSIP gene, precursor protein, or specific receptor had been isolated. Antibody tests had found "DSIP-like" signals in animal and human tissues, but antibodies can react to similar protein fragments rather than authentic DSIP.
In 2011 in the journal Peptides, Inessa I. Mikhaleva and colleagues at the Russian Academy of Sciences in Moscow searched protein databases. They found a related nine-amino-acid sequence inside JMJD1B-type proteins that differed from DSIP at two positions. The Moscow group proposed those proteins as candidate precursors for DSIP-like activity, without establishing how the body makes DSIP itself.
From compounding history to DSIP's status today
Decades after the Basel publications, DSIP entered compounding practice under both its original name and the common name emideltide. According to a July 24, 2026 FDA presentation, emideltide is an informal common name rather than an official international or U.S. drug name. In that same review, FDA staff traced compounding with forms of emideltide back to at least 2018.
As of October 17, 2026, the day this article was written, the FDA's latest review was its July 23–24, 2026 advisory committee meeting. The agency evaluated emideltide free base and emideltide acetate for chronic insomnia, narcolepsy, and opioid withdrawal. FDA staff proposed excluding both forms from the 503A Bulks List, and advisory committee recommendations to the agency are non-binding.
In its July 2026 briefing document, the FDA noted that 209 people had received intravenous emideltide for 1 to 15 days across published studies. Three patients in an uncontrolled withdrawal study had serious adverse effects, including progressive hypotension (falling blood pressure), though withdrawal complicated the cause.
The FDA's bulk drug substances safety page places emideltide in its withdrawn-nominations table. The agency notes potential immune-response and impurity risks and lacks human safety data for under-the-skin use, which we cover in DSIP side effects.
There is no FDA-approved drug that contains either form of emideltide. Compounded DSIP is different from an FDA-approved product: the formulation offered here is not FDA-approved. Regulatory status is one part of care, and a licensed provider may still prescribe — that decision is between you and your doctor.
DSIP prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy. At Promise, a licensed provider reviews every request, and not everyone qualifies.
